Polymer Drugs in the Clinical Stage Advantages and Prospects /

Proceedings of the International Symposium on Polymer Therapeutics - Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan. The technology of polymer science has developed considerably during the past half-century, and this volume describes some of the aspects of thi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Maeda, Hiroshi (Επιμελητής έκδοσης), Kabanov, Alexander (Επιμελητής έκδοσης), Kataoka, Kazunori (Επιμελητής έκδοσης), Okano, Teruo (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Boston, MA : Springer US, 2003.
Σειρά:Advances in Experimental Medicine and Biology, 519
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04355nam a22005775i 4500
001 978-0-306-47932-8
003 DE-He213
005 20151103122545.0
007 cr nn 008mamaa
008 100301s2003 xxu| s |||| 0|eng d
020 |a 9780306479328  |9 978-0-306-47932-8 
024 7 |a 10.1007/b105364  |2 doi 
040 |d GrThAP 
050 4 |a RM1-950 
072 7 |a MMG  |2 bicssc 
072 7 |a MED071000  |2 bisacsh 
082 0 4 |a 615  |2 23 
245 1 0 |a Polymer Drugs in the Clinical Stage  |h [electronic resource] :  |b Advantages and Prospects /  |c edited by Hiroshi Maeda, Alexander Kabanov, Kazunori Kataoka, Teruo Okano. 
264 1 |a Boston, MA :  |b Springer US,  |c 2003. 
300 |a VIII, 226 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Advances in Experimental Medicine and Biology,  |x 0065-2598 ;  |v 519 
505 0 |a Challenges in Polymer Therapeutics -- Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS -- PEG-Adenosine Deaminase and PEG-Asparaginase -- Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C -- PEG-Methioninase -- Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate -- HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer -- Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer -- CM-Dextran-Polyalcohol-Camptothecin Conjugate -- Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs -- An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer -- Polymer Conjugates for Imaging -- S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics. 
520 |a Proceedings of the International Symposium on Polymer Therapeutics - Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan. The technology of polymer science has developed considerably during the past half-century, and this volume describes some of the aspects of this technology that will have a great impact in the future. Among these advances, for example, are gene delivery to specific disease sites and carrier polymers that respond to a stimulus or particular environment. Cancer targeted drug delivery is another focused area of this volume because of the important nature of EPR-effect of polymer drugs in tumor. Included are discussions of as many examples as possible of polymer drugs that have achieved, or are close to clinical use. The concept of "Polymer drugs" here is limited to primarily injectable and water-soluble agents, although also covered are some drugs in micellar form or liposomes. This book is intended for students and researchers in the field of pharmacology who have particular interests in drug delivery, targeting, and formulation, as well as for clinicians such as oncologists who are interested in the field. People who work at regulatory agencies should also be aware such that drugs with great potential are being developed and will be beneficial to many patients, as well as to health insurance agencies because of improved cost effectiveness. 
650 0 |a Medicine. 
650 0 |a Pharmacy. 
650 0 |a Pharmacology. 
650 0 |a Polymers. 
650 0 |a Oncology. 
650 0 |a Medical biochemistry. 
650 1 4 |a Biomedicine. 
650 2 4 |a Pharmacology/Toxicology. 
650 2 4 |a Polymer Sciences. 
650 2 4 |a Medical Biochemistry. 
650 2 4 |a Oncology. 
650 2 4 |a Pharmacy. 
700 1 |a Maeda, Hiroshi.  |e editor. 
700 1 |a Kabanov, Alexander.  |e editor. 
700 1 |a Kataoka, Kazunori.  |e editor. 
700 1 |a Okano, Teruo.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9780306474712 
830 0 |a Advances in Experimental Medicine and Biology,  |x 0065-2598 ;  |v 519 
856 4 0 |u http://dx.doi.org/10.1007/b105364  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
912 |a ZDB-2-BAE 
950 |a Biomedical and Life Sciences (Springer-11642)